Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Arthritis Research & Therapy
Published in: Arthritis Research & Therapy 1/2012

Open Access 01-12-2012 | Oral presentation

Future direction of pathogenesis and treatment for rheumatic disorders

Author: Steffen Gay

Published in: Arthritis Research & Therapy | Special Issue 1/2012

Login to get access

Excerpt

After the breakthrough in the treatment of rheumatoid arthritis and numerous related disorders with biological therapies targeting TNFa at the Kennedy Institute in London …
Literature
1.
2.
Karouzakis E, et al: Epigenetic control in rheumatoid arthritis synovial fibroblasts. Nat Rev Rheumatol. 2009, 5: 266-72. 10.1038/nrrheum.2009.55.CrossRefPubMed
3.
Brock M, et al: Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. Circ Res. 2009, 104: 1184-91. 10.1161/CIRCRESAHA.109.197491.CrossRefPubMed
4.
Stanczyk J, et al: Altered expression of miRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation. Arthritis Rheum. 2011, 63: 373-81. 10.1002/art.30115.PubMedCentralCrossRefPubMed
5.
Metadata
Title
Future direction of pathogenesis and treatment for rheumatic disorders
Author
Steffen Gay
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Arthritis Research & Therapy / Issue Special Issue 1/2012
Electronic ISSN: 1478-6362
DOI
https://doi.org/10.1186/ar3556

Other articles of this Special Issue 1/2012

Arthritis Research & Therapy 1/2012 Go to the issue

Poster presentation

IL-17-producing ©™T cells are important for the development of arthritis in a rheumatoid arthritis model

Oral presentation

Adult stem cell-based therapy for degenerative joint diseases

Oral presentation

A novel NEDD8-binding protein modulates NF-κB signaling pathway

Poster presentation

Active repression by Blimp1 play an important role in osteoclast differentiation

Poster presentation

Stimulation of bone formation in cortical bone of the mice treated with a novel bone anabolic peptide with osteoclastogenesis inhibitory activity

Oral presentation

Postnatal Syk deletion in mice clarifies the function of Syk in an anti-collagen antibody-induced arthritis model
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits